Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside analog, and an anthracycline (most often daunorubucin). About 60-70% of patients achieved complete remission after this standard chemotherapy. As cytarabine competes with endogenous nucleotides to exert its activity, the aim of this protocol is to study in vivo the effect of intracellular nucleotide pools on the efficacy of the induction treatment. Thus, intracellular nucleotides levels will be determined in peripheral blood mononuclear cells of patients with acute myeloid leukemia before treatment, and results will be compared with the efficacy of the treatment. This parameter will be assessed by the achievement of complete remission.

Patients Inclusion Criteria:

• age over 18 years
• acute myeloid leukemia
• standard induction chemotherapy with cytarabine and daunorubicin
• patients who received the information and did not object to participate to the study

Patients Exclusion Criteria:

- patients with acute myeloid leukemia 3

healthy volunteers Inclusion Criteria :

• adults without known hematological disease,
• adults who received the information and did not object to participate in the study

healthy volunteers Exclusion Criteria :

- Volunteers with known hematological disease.

Patients or healthy volunteers over 18 years with acute myeloid leukemia (except acute myeloid leukemia3)